Press release
Non-Alcoholic Steatohepatitis Treatment Market: Surge in Market Size, Growth Rate, and Trends Driven by Clinical Research and Advancements in Drug Development
Non-Alcoholic Steatohepatitis Treatment Market
The non-alcoholic steatohepatitis treatment market is booming, making a significant leap from $2.6 billion in 2024 to an expected $13.83 billion in 2029. The key growth drivers include increased disease awareness, innovations in drug development, and a shift towards personalized medicine.
What Is The Projected Market Size Of The Global Non-Alcoholic Steatohepatitis Treatment Market And Its Growth Rate?
• The market has shown substantial growth, escalating from $2.6 billion in 2024 to $3.6 billion in 2025 with a CAGR of 38.5%.
• Factors contributing to this historic period growth include lifestyle changes, obesity epidemic, rising NASH prevalence, improving access to healthcare, and regulatory support.
• The market size is projected to reach $13.83 billion in 2029 with a CAGR of 40.0%, owing to advancements in drug development and a surge in disease prevalence.
What Is Driving The Growth In The Non-Alcoholic Steatohepatitis Treatment Market?
An increased prevalence of insulin resistance primarily propels the non-alcoholic steatohepatitis treatment market. High blood sugar levels, brought on by cells' inability to absorb glucose from the bloodstream, often lead to conditions treatable with non-alcoholic steatohepatitis treatments. Given the escalating number of individuals affected by diabetes and other liver-related issues, the market is expected to see substantial growth.
Request A Free Sample Copy: https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
Who Are The Key Players Driving Non-Alcoholic Steatohepatitis Treatment Market Growth?
• AstraZeneca PLC
• Galmed Pharmaceuticals Ltd.
• Genfit S.A.
• Zydus Cadila Healthcare Limited
• Bristol-Myers Squibb Company
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Immuron Ltd.
• Inventiva Pharma SA
• NGM Biopharmaceuticals Inc.
• Galectin Therapeutics Inc.
• Madrigal Pharmaceuticals Corporation
• Intercept Pharmaceuticals Inc.
• Cirius Therapeutics Inc.
• Viking Therapeutics Inc.
• Eli Lilly and Company
• Terns Pharmaceuticals Inc.
• Pfizer Inc.
• Merck & Co. Inc.
• AbbVie Inc.
• Johnson & Johnson Private Limited
• Sanofi S.A.
• F. Hoffmann-La Roche Ltd.
• C.H. Boehringer Sohn AG & Co. KG
What Are The Key Trends In The Non-Alcoholic Steatohepatitis Treatment Market?
• A patient-centric approach in treatment planning and delivery.
• Deployment of technological advancements in diagnostics and treatment.
• Rise in targeted therapies for personalized treatment.
• Evolving regulatory landscape supporting innovations.
• Advancements in research promoting drug development.
What Are The Segments Of The Global Non-Alcoholic Steatohepatitis Treatment Market?
1) Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drug Types
2) Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Which Region Leads The Non-Alcoholic Steatohepatitis Treatment Market?
North America dominated the non-alcoholic steatohepatitis treatment market in 2024. Market coverage extends to Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa regions.
Pre-book the Report for Swift Delivery: https://www.thebusinessresearchcompany.com/report/non-alcoholic-steatohepatitis-treatment-global-market-report
What Is Covered In The Non-Alcoholic Steatohepatitis Treatment Market Global Market Report?
- Market Size Analysis: Analyze the Non-Alcoholic Steatohepatitis Treatment Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Non-Alcoholic Steatohepatitis Treatment Market for effective categorization.
- Key Player Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Non-Alcoholic Steatohepatitis Treatment Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Non-Alcoholic Steatohepatitis Treatment Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
[Request Customization for This Report]
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Non-Alcoholic Steatohepatitis Treatment Market: Surge in Market Size, Growth Rate, and Trends Driven by Clinical Research and Advancements in Drug Development here
News-ID: 3822211 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Steatohepatitis
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASH…
Non-Alcoholic Steatohepatitis Treatment Market Size, Share
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $2.67 billion In 2028…
Non-Alcoholic Steatohepatitis (NASH) - Drug Pipeline Landscape, 2023
Nonalcoholic steatohepatitis (NASH) is a type of fatty liver disease. It is characterized by the accumulation of fat in the liver, inflammation, and damage. NASH can lead to cirrhosis, liver failure, and death. The exact cause of NASH is unknown, but it is believed to be associated with obesity, insulin resistance, and diabetes. Treatment of NASH is focused on weight loss, exercise, and the control of diabetes and insulin resistance.
NASH…
Non Alcoholic Steatohepatitis (NASH) Market Size to Hit $21,879 Million by 2028 …
According to our experience research team, Non Alcoholic Steatohepatitis (NASH) Market was valued at USD 1,569 Million in 2021, and the global Non Alcoholic Steatohepatitis (NASH) industry is projected to reach a value of USD 21,879 Million by 2028, at a CAGR of 60.4% during the forecast period 2022-2028
The report is focused on gaining various Non Alcoholic Steatohepatitis (NASH) market trends, dynamics, growth drivers, opportunities, weaknesses, strengths, and threats restraining…
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'…
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likely…
